瑞他鲁肽 Retatrutide

Retatrutide is the first drug to activate all three major metabolic receptors — GLP-1, GIP, and glucagon — in a single molecule. In its Phase 2 obesity trial, participants taking the highest dose lost a mean of 24.2% of their body weight over 48 weeks.^[1] That's a bigger number than any approved weight-loss drug has produced in a comparable timeframe.

It's developed by Eli Lilly under the compound designation LY3437943, and it's currently in Phase 3 trials. You can't get it yet — not from a clinic, not from a compounding pharmacy, not legally from any source. But if the Phase 3 data holds up, it could become the most effective pharmacological obesity treatment ever approved.

Key Takeaways

• Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously — the only drug in its class to do all three.
• Phase 2 trials showed mean weight loss of 24.2% at the 12 mg dose over 48 weeks, the highest figure reported for any obesity drug to date.^[1]

It is strictly investigational as of early 2026 — no FDA approval, no compounding pathway, no legal access outside enrolled clinical trials.

GI side effects (nausea, vomiting, diarrhea) are the dominant safety signal, consistent with the broader GLP-1 drug class, and are most pronounced during dose escalation.

Phase 3 cardiovascular outcomes data does not yet exist — a meaningful gap given that semaglutide's SELECT trial changed prescribing practice for the whole class.

Class	Triple Incretin Agonist
Mechanism	GLP-1 + GIP + Glucagon receptor agonism
Developer	Eli Lilly (LY3437943)
FDA Status	Investigational — Phase 3 ongoing
Administration	Subcutaneous injection, once weekly
Trial Dose Range	2 mg → 12 mg once weekly, escalated over ~24 weeks
Half-life	~6 days — half-life not established in available clinical trial data
Primary Uses	Obesity, Type 2 Diabetes

The Phase 2 obesity trial tested four active doses — 2 mg, 4 mg, 8 mg, and 12 mg — all administered once weekly by subcutaneous injection.^[1] Participants didn't start at their assigned maintenance dose. They escalated gradually over roughly 24 weeks, with the 12 mg group passing through 2 mg and 4 mg steps before reaching the top dose. That slow ramp is deliberate: it's how you get the GI side effects down to a manageable level.

24.2% mean weight loss at 12 mg over 48 weeks — Phase 2 obesity trial (PMID 37366315)

The dose-response relationship was clear and steep. Higher doses produced meaningfully better outcomes, and the curve hadn't obviously flattened by 12 mg — which is one reason Phase 3 is exploring whether even higher doses might be tolerated and effective.

Dose-Response: Phase 2 Obesity Trial (48 Weeks)

Outcome	4 mg	8 mg	12 mg
Mean weight loss	~8.7%	~17.3%	~24.2%
Placebo-adjusted loss	~7.0%	~15.6%	~22.5%
≥5% weight loss (responders)	~75%	~91%	~100%
≥15% weight loss (responders)	~27%	~67%	~83%
≥25% weight loss (responders)	~5%	~30%	~42%

The responder data at 12 mg is striking: roughly 83% of participants lost at least 15% of their body weight, and about 42% lost 25% or more.^[1] For context, 15% weight loss is the threshold where most obesity-related comorbidities — hypertension, sleep apnea, joint disease — begin to meaningfully improve.

Because retatrutide has no approved indication and no legal commercial pathway, these doses are not prescribable. They exist as reference data for understanding what the drug does. If Phase 3 trials succeed and the FDA approves retatrutide, the approved dose range may differ from what Phase 2 tested. Check ClinicalTrials.gov for current trial protocols.

Dosing References and Calculator

For readers researching how the trial milligram doses translate into reconstitution volumes and insulin-syringe units at different vial concentrations, we maintain vial-specific dosing references and a dedicated calculator:

• Retatrutide 5 mg vial dosing protocol
• Retatrutide 10 mg vial dosing protocol
• Retatrutide 20 mg vial dosing protocol
• Retatrutide 30 mg vial dosing protocol
• Retatrutide dosage calculator — convert any milligram dose to insulin-syringe units for your specific vial and bacteriostatic-water setup

These references only summarize the milligram-to-units arithmetic reported in the trial literature. Because retatrutide is investigational, they are not a recommendation to obtain or self-administer it outside a clinical trial.

Every GLP-1 drug on the market — semaglutide, liraglutide — hits one receptor. Tirzepatide added a second, GIP, and the results were noticeably better than single-agonist drugs. Retatrutide adds a third: the glucagon receptor.

That third target is what makes this compound pharmacologically distinct. Glucagon receptor activation increases energy expenditure — your body burns more calories at rest. It also has direct effects on fat metabolism in the liver, which is why retatrutide is being studied for metabolic-associated steatotic liver disease (MASLD) alongside obesity.^[2] GLP-1 and GIP handle the appetite and insulin side of the equation; glucagon handles the energy output side. Hitting all three simultaneously is what the Phase 2 numbers reflect.

Why the glucagon receptor matters

Glucagon is usually thought of as the hormone that raises blood sugar — the opposite of insulin. But glucagon receptor agonism at the right dose, in the context of GLP-1 co-activation, doesn't cause problematic hyperglycemia. Instead, it increases thermogenesis (heat production and calorie burning) and promotes fat breakdown in the liver. The GLP-1 component essentially counterbalances the blood sugar effect while the glucagon component adds metabolic drive that GLP-1 alone can't provide.

Start with what you already know about GLP-1 drugs: they slow gastric emptying, reduce appetite, and improve insulin secretion in a glucose-dependent way. That's the foundation. Retatrutide does all of that — and then adds two more layers.

The GIP receptor component amplifies the insulin response and appears to improve how fat tissue handles energy storage and release.^[3] This is the same receptor tirzepatide targets alongside GLP-1, and it's part of why dual agonists outperformed pure GLP-1 drugs in head-to-head comparisons.

The glucagon receptor layer is what's new. Glucagon receptor agonism increases basal metabolic rate — your resting calorie burn goes up. It also drives fatty acid oxidation in the liver, which is why retatrutide showed signals for liver fat reduction in the Phase 2 diabetes trial.^[2] The net effect is a drug that suppresses intake (GLP-1 + GIP), improves insulin dynamics (GLP-1 + GIP), and increases output (glucagon) — all three levers pulled at once.

The glucose-dependent nature of the GLP-1 and GIP components matters for safety: insulin secretion is amplified only when blood glucose is elevated, which limits hypoglycemia risk compared to older diabetes drugs like sulfonylureas.

Phase 2 Obesity Trial

The Phase 2 obesity trial published in the New England Journal of Medicine in 2023 is the primary efficacy data we have.^[1] Participants were adults with obesity or overweight plus at least one weight-related comorbidity, without diabetes. The trial ran 48 weeks at maintenance dose, following a ~24-week escalation period.

At the 12 mg dose, mean weight loss was 24.2% — roughly 58 lbs from a starting weight around 240 lbs. To put that in BMI (body mass index) terms: a participant starting at a BMI of 38 would end near 29, crossing from obese to overweight. The 8 mg dose produced approximately 17.3% weight loss, and 4 mg produced approximately 8.7%.^[1]

Phase 2 Type 2 Diabetes Trial

The Lancet published the Phase 2 diabetes trial alongside the obesity data in 2023.^[2] In people with type 2 diabetes, retatrutide produced dose-dependent reductions in HbA1c (a 90-day average of blood glucose levels) of up to 2.2 percentage points at the highest dose — a clinically meaningful reduction that would move many patients from poorly controlled to well-controlled diabetes. Weight loss in this population reached approximately 16.9% at the highest dose over 36 weeks, somewhat lower than the non-diabetic obesity trial, which is consistent with what's seen across the GLP-1 class.^[2]

Where Retatrutide Fits in the Broader Class

A 2024 review in Diabetes Care and a 2025 systematic review in Annals of Internal Medicine both position retatrutide as the leading edge of a new generation of incretin-based therapies, with the triple agonist mechanism producing the highest weight loss percentages seen in any pharmacological trial to date.^[3][4] Neither review changes the fundamental status: Phase 2 data, no Phase 3 results yet, no approved indication.

“ Retatrutide is the first drug to hit all three metabolic receptors simultaneously — and the Phase 2 numbers suggest that distinction matters. ”

What We Don't Know Yet

• Long-term safety — Phase 2 ran 48 weeks. There's no data on what happens at 2, 3, or 5 years of continuous use.
• Cardiovascular outcomes — Semaglutide's SELECT trial demonstrated a 20% reduction in major cardiovascular events. Retatrutide has no comparable outcomes trial yet. This is a significant gap.
• Weight regain after stopping — The class-wide pattern is significant regain after discontinuation. Whether retatrutide's higher weight loss translates to better or worse regain dynamics is unknown.
• Head-to-head comparisons — No direct trials against tirzepatide or semaglutide exist. Cross-trial comparisons are unreliable because populations, durations, and endpoints differ.
• Liver disease outcomes — Phase 2 showed signals for liver fat reduction, but no confirmed MASLD/NASH outcomes data exists yet.
• Bone density and muscle mass — Rapid large-magnitude weight loss raises questions about lean mass preservation. Phase 2 didn't fully characterize this.

The side effect profile looks like the rest of the GLP-1 class, amplified somewhat by the higher weight loss and the glucagon component. The Phase 2 trials provide the most reliable data we have.^[1][2]

During dose escalation (roughly weeks 1–24):

• Nausea — the most commonly reported side effect across both Phase 2 trials; most pronounced in the 24–48 hours after each injection and tends to improve as the body adjusts at each dose step.
• Vomiting — reported less frequently than nausea; more common at higher doses and during escalation steps.
• Diarrhea — reported during escalation; typically transient.
• Decreased appetite — technically an intended effect, but worth noting that appetite suppression can be intense enough in some participants to require dose pauses.

At stable maintenance dose:

• Constipation — more common at higher doses and later in treatment, consistent with the GLP-1 class pattern of slowed GI motility.
• Injection site reactions — mild redness or tenderness at the injection site; rotating sites (abdomen, thigh, upper arm) reduces this.
• Fatigue — reported in Phase 2, particularly during escalation phases.

Rare but worth knowing:

• Pancreatitis risk — a class-level concern shared with all GLP-1 drugs; no cases were confirmed in Phase 2, but the theoretical risk exists and warrants monitoring.
• Gallbladder events — rapid significant weight loss increases gallstone risk; this is a known concern across the GLP-1 class.
• Tachycardia (elevated resting heart rate) — the glucagon receptor component may contribute to modest increases in resting heart rate; elevated resting heart rate has been observed in clinical trials and may warrant cardiovascular monitoring, though the specific contribution of the glucagon receptor component requires further characterization.

If you're enrolled in a retatrutide trial and experience severe abdominal pain (possible pancreatitis), significant changes in heart rate, or GI symptoms that prevent normal eating or hydration, contact your trial coordinator immediately — don't wait for your next scheduled visit.

Access status as of 2026-03

Retatrutide has no FDA approval and no legal commercial pathway in the United States. It is not available through compounding pharmacies, telehealth clinics, or any retail or online vendor. The only legal access is enrollment in Eli Lilly's ongoing Phase 3 clinical trials. If you encounter a source claiming to sell retatrutide, it is either mislabeled, counterfeit, or operating outside the law.

Retatrutide is classified as an investigational new drug (IND) under FDA oversight. Phase 3 trials are ongoing as of early 2026. If those trials succeed and Eli Lilly files a New Drug Application (NDA), FDA review typically takes 6–12 months from filing. A realistic approval timeline, if Phase 3 data is positive, would be no earlier than 2026–2027 — and that's contingent on the trials meeting their endpoints.

To find active trials you may be eligible for, search ClinicalTrials.gov for "retatrutide" or "LY3437943." Eligibility criteria vary by trial; most obesity trials require a BMI of 30 or above, or 27 or above with a weight-related comorbidity.

The FDA has taken enforcement action against companies marketing unapproved peptide and GLP-1 class products. Patients and providers should consult FDA.gov and the FDA's MedWatch program for current enforcement activity.

The honest answer is: we don't know yet, because no head-to-head trial exists. What we have are Phase 2 numbers for retatrutide and Phase 3 numbers for the approved drugs — different populations, different durations, different study designs. Cross-trial comparisons can tell you something directionally, but they can't tell you definitively that retatrutide is "better."

With that caveat clearly stated, here's what the trial data shows:

Weight Loss: GLP-1 Class Comparison

Parameter	Retatrutide	Tirzepatide	Semaglutide
Peak mean weight loss	~24.2% (48 wk)	~22.5% (72 wk)	~14.9% (68 wk)
Trial phase	Phase 2	Phase 3 (SURMOUNT-1)	Phase 3 (STEP 1)
Receptors targeted	GLP-1 + GIP + Glucagon	GLP-1 + GIP	GLP-1
FDA status	Investigational	Approved (obesity)	Approved (obesity)
Available now?	No	Yes	Yes
CV outcomes trial	No	Ongoing	Yes (SELECT)
Administration	SC weekly	SC weekly	SC weekly

Tirzepatide and semaglutide are both approved and accessible now. Retatrutide may eventually outperform both on weight loss, but "may" is doing a lot of work in that sentence until Phase 3 data exists. For someone deciding between available options today, the approved drugs are the practical choice. For someone interested in what's coming, retatrutide is the most closely watched compound in the pipeline.

For a deeper comparison, see our retatrutide vs tirzepatide breakdown.

The Phase 2 data is genuinely impressive. It is also genuinely limited. Here's what you should not conclude from it:

• Phase 2 ≠ Phase 3. Many drugs with strong Phase 2 results fail or show diminished effects in larger Phase 3 trials. The STEP and SURMOUNT programs both confirmed their Phase 2 signals, but that's not guaranteed for retatrutide.
• 48 weeks ≠ long-term safety. The trial duration is not long enough to characterize risks that emerge over years of use — bone density changes, sustained cardiovascular effects, or rare adverse events with low incidence.
• Weight loss ≠ cardiovascular benefit. Semaglutide's SELECT trial showed that weight loss alone doesn't explain the cardiovascular benefit — there appear to be direct cardiac effects. Whether retatrutide has similar benefits, better benefits, or different risks due to the glucagon component is unknown.
• Phase 2 population ≠ real-world population. Clinical trial participants are selected, monitored closely, and supported throughout. Real-world adherence, side effect management, and outcomes typically differ from trial conditions.